

# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mr. PREM SINGH

AGE/ GENDER : 58 YRS/MALE **PATIENT ID** : 1769594

**COLLECTED BY** REG. NO./LAB NO. : 122502260016

REFERRED BY **REGISTRATION DATE** : 26/Feb/2025 10:34 AM BARCODE NO. **COLLECTION DATE** : 26/Feb/2025 10:50AM : 12507244 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 26/Feb/2025 01:05PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value Test Name** Unit **Biological Reference interval** 

#### CLINICAL CHEMISTRY/BIOCHEMISTRY

**LIPID PROFILE: BASIC** 

CHOLESTEROL TOTAL: SERUM OPTIMAL: < 200.0 228.21<sup>H</sup> mg/dL

by CHOLESTEROL OXIDASE PAP BORDERLINE HIGH: 200.0 -

2390

HIGH CHOLESTEROL: > OR =

240.0

TRIGLYCERIDES: SERUM OPTIMAL: < 150.0 381.03<sup>H</sup> mg/dL by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) BORDERLINE HIGH: 150.0 -

199.0

HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM LOW HDL: < 30.0 mg/dL 28.76<sup>L</sup>

by SELECTIVE INHIBITION

BORDERLINE HIGH HDL: 30.0 -

60.0

 $HIGH\ HDL: > OR = 60.0$ LDL CHOLESTEROL: SERUM 123.24 OPTIMAL: < 100.0 mg/dL

by CALCULATED, SPECTROPHOTOMETRY ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 -

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM 199.45<sup>H</sup> mg/dL OPTIMAL: < 130.0 by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 -

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

mg/dL VLDL CHOLESTEROL: SERUM 76.21<sup>H</sup> 0.00 - 45.00

by CALCULATED. SPECTROPHOTOMETRY

TOTAL LIPIDS: SERUM

350.00 - 700.00 837.45<sup>H</sup> mg/dL by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM 7.93<sup>H</sup> RATIO LOW RISK: 3.30 - 4.40 by CALCULATED, SPECTROPHOTOMETRY

AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







# PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

### A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

**NAME** : Mr. PREM SINGH

AGE/ GENDER : 58 YRS/MALE **PATIENT ID** : 1769594

**COLLECTED BY** : 122502260016 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 26/Feb/2025 10:34 AM BARCODE NO. **COLLECTION DATE** : 26/Feb/2025 10:50AM : 12507244 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 26/Feb/2025 01:05PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	<b>Biological Reference interval</b>
			MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	4,29 <sup>H</sup>	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	13.25 <sup>H</sup>	RATIO	3.00 - 5.00

#### INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)